Revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Abbott Laboratories (ABT)
Price$101.05Cached quote
Net income
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B | $34.61B | $31.90B | $30.58B | $27.39B | $20.85B | $20.41B | $20.25B | $19.66B | $19.05B | $21.41B | $35.17B | $30.76B | $29.53B | $25.91B |
| Gross profit | $25.01B | $23.24B | $22.13B | $24.51B | $24.54B | $19.61B | $18.67B | $17.87B | $14.98B | $11.76B | $11.66B | $11.03B | $10.46B | $10.15B | $11.39B | $20.50B | $17.56B | $16.92B | $14.49B |
| Gross margin | 56.42% | 55.41% | 55.18% | 56.15% | 56.97% | 56.65% | 58.53% | 58.45% | 54.70% | 56.39% | 57.13% | 54.47% | 53.23% | 53.29% | 53.21% | 58.30% | 57.06% | 57.29% | 55.92% |
| Research & development | $2.94B | $2.84B | $2.74B | $2.89B | $2.74B | $2.42B | $2.44B | $2.30B | $2.26B | $1.45B | $1.41B | $1.34B | $1.37B | $1.46B | $1.51B | $3.72B | $2.74B | $2.69B | $2.51B |
| Operating expenses | $36.27B | $35.13B | $33.63B | $35.29B | $34.65B | $29.25B | $27.37B | $26.93B | $25.83B | $17.83B | $17.54B | $17.65B | $17.52B | $17.69B | $19.78B | $29.08B | $24.53B | $23.83B | $21.34B |
| Operating income | $8.05B | $6.83B | $6.48B | $8.36B | $8.43B | $5.36B | $4.53B | $3.65B | $1.56B | $3.03B | $2.87B | $2.60B | $2.13B | $1.36B | $1.63B | $6.09B | $6.24B | $5.69B | $4.58B |
| Operating margin | 18.17% | 16.27% | 16.15% | 19.16% | 19.56% | 15.48% | 14.21% | 11.94% | 5.71% | 14.51% | 14.05% | 12.84% | 10.85% | 7.14% | 7.61% | 17.31% | 20.27% | 19.28% | 17.67% |
| EBITDA | $11.17B | $10.04B | $9.72B | $11.63B | $11.96B | $8.68B | $7.55B | $6.93B | $4.58B | $4.38B | $4.34B | $4.15B | $3.85B | $4.14B | $4.67B | $8.71B | $8.33B | $7.53B | $6.43B |
| EBITDA margin | 25.20% | 23.94% | 24.24% | 26.64% | 27.77% | 25.09% | 23.65% | 22.66% | 16.74% | 21.00% | 21.26% | 20.48% | 19.60% | 21.74% | 21.83% | 24.77% | 27.06% | 25.51% | 24.83% |
| Net income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B | $4.50B | $3.69B | $2.37B | $477.0M | $1.40B | $4.42B | $2.28B | $2.58B | $5.96B | $4.73B | $4.63B | $5.75B | $4.88B | $3.61B |
| Net profit margin | 14.72% | 31.95% | 14.27% | 15.88% | 16.42% | 12.99% | 11.56% | 7.74% | 1.74% | 6.71% | 21.68% | 11.28% | 13.10% | 31.30% | 22.09% | 13.15% | 18.68% | 16.53% | 13.92% |
| Basic EPSper basic share | $3.73 | $7.67 | $3.28 | $3.94 | $3.97 | $2.52 | $2.07 | $1.34 | $0.27 | $0.94 | $2.94 | $1.50 | $1.64 | $3.76 | $3.03 | $2.98 | $3.71 | $3.16 | $2.34 |
| Diluted EPSper diluted share | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 | $2.50 | $2.06 | $1.33 | $0.27 | $0.94 | $2.92 | $1.49 | $1.62 | $3.72 | $3.01 | $2.96 | $3.69 | $3.12 | $2.31 |
Owners
Reported shareholders
8.82%of listed shares
BlackRock, Inc.152.56M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 8.82%152.56M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 6.57%113.75M shares |
STATE STREET CORP | 4.68%80.93M shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3.45%59.67M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 2.83%49.02M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.27%39.22M shares |
Capital Research Global Investors | 2.13%36.91M shares |
Capital International Investors | 2.00%34.65M shares |
MORGAN STANLEY | 1.54%26.61M shares |
NORGES BANK | 1.35%23.35M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 1.32%22.79M shares |
FRANKLIN RESOURCES INC | 1.09%18.81M shares |
NORTHERN TRUST CORP | 1.06%18.27M shares |
BANK OF AMERICA CORP /DE/ | 1.02%17.67M shares |
GOLDMAN SACHS GROUP INC | 0.97%16.76M shares |
DEUTSCHE BANK AG\ | 0.97%16.71M shares |
WELLS FARGO & COMPANY/MN | 0.88%15.18M shares |
JPMORGAN CHASE & CO | 0.87%15.1M shares |
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | 0.79%13.59M shares |
FMR LLC | 0.78%13.42M shares |
Percentages use 1.73B shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 7, 2026Form 4 | Stratton John GDirector | BuyCommon shares without par value | 2.0K | $86.82 | $173.6K | 23.3K |
| Apr 27, 2026Form 4 | STARKS DANIEL JDirector | BuyCommon shares without par value | 10.0K | $92.65 | $926.5K | 6.75M |
| Apr 23, 2026Form 4 | Boudreau Philip PEVP AND CFO | BuyCommon shares without par value · indirect | 2.2K | $91.50 | $201.3K | 2.2K |
| Mar 2, 2026Form 4 | Cushman Elizabeth C.EVP, GC AND SECRETARY | SellCommon shares without par value | 263 | $115.58 | $30.4K | 38.6K |
| Mar 2, 2026Form 4 | Shroff EricSenior Vice President | SellCommon shares without par value | 709 | $115.58 | $81.9K | 39.2K |
Community posts
Abbott launches blood-based colorectal cancer screening test in the US
Abbott ($ABT) has launched SimpleScreen CRC in the United States, adding an FDA-approved blood test to its colorectal cancer screening portfolio. Freenome develops and manufactures the test, while Abbott holds exclusive commercialization ri ...
Abbott agrees to $385 million settlement over infant-formula recall claims
Abbott ($ABT) said it will pay $385 million to resolve a previously disclosed Justice Department investigation and lawsuit, together with claims brought by certain whistleblowers and state attorneys general. The matters concern manufacturin ...
